34 citations,
November 2013 in “Breast Cancer Research and Treatment” Aromatase inhibitor therapy for breast cancer increases the risk of hair loss and thinning.
28 citations,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
24 citations,
November 2013 in “British Journal of Dermatology” Chemotherapy causes hair loss starting soon after treatment begins and recovers about 3 months after ending, while tamoxifen does not significantly affect hair growth.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
19 citations,
June 2018 in “Breast Cancer Research and Treatment” Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.
17 citations,
June 2001 in “Journal of the National Cancer Institute” A specific hair diffraction pattern may indicate breast cancer if tested with the correct method.
15 citations,
May 1997 in “Annals of Internal Medicine” Tamoxifen caused hair loss in a 52-year-old woman.
10 citations,
May 2020 in “Journal of The American Academy of Dermatology” Taking spironolactone doesn't increase the chance of breast cancer coming back.
7 citations,
December 2021 in “Curēus” Breast cancer skin metastases are rare, look different, and can be confused with other skin issues, so a biopsy is needed for accurate diagnosis.
3 citations,
January 2021 in “Skin appendage disorders” Hair loss due to scalp metastasis from breast cancer, known as Neoplastic Alopecia, has a better survival rate than other scalp metastases and requires a biopsy for diagnosis.
3 citations,
July 2019 in “Supportive Care in Cancer” The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
2 citations,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
July 2020 in “Journal of the American Academy of Dermatology” Spironolactone does not increase the risk of breast cancer recurrence.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
October 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
June 2019 in “Research Square (Research Square)” YH0618 granules may help prevent hair loss in breast cancer patients undergoing chemotherapy.
September 2016 in “Oncology times” Breast cancer survivors often face body image and sexual health issues, needing ongoing support and open communication with healthcare providers.
March 2010 in “Ejc Supplements” Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.
June 1995 in “International Journal of Gynecology & Obstetrics” Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.
March 2010 in “Ejc Supplements” ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
April 2023 in “International Journal of Women's Dermatology” Spironolactone is safe for breast cancer survivors with alopecia and does not increase cancer risk.
22 citations,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
108 citations,
December 2003 in “Clinical breast cancer” PLD is an effective and safer alternative for treating breast cancer.
68 citations,
May 2012 in “Annals of Oncology” Some breast cancer chemotherapy can cause permanent hair loss.
67 citations,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
59 citations,
August 2018 in “The oncologist” Some breast cancer patients still experience hair loss three years after chemotherapy, especially with taxane-based treatments.
32 citations,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
31 citations,
March 2017 in “Journal of The American Academy of Dermatology” Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.
18 citations,
August 2019 in “Clinical breast cancer” Local hormonal treatment for vulvovaginal atrophy is likely safe for women with estrogen receptor-positive breast cancer on aromatase inhibitors.